JW Shinyak Corporation (067290.KQ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7067290007

Price
2,235.00 KRW
Market cap
124.89 bn KRW
P/E (2025)
7.98
P/S (2025)
1.54
Dividend yield
0.00 %
Net margin
19.32 %
Return on equity (ROE)
38.44 %
Return on assets (ROA)
26.88 %

JW Shinyak Corporation financials

Fiscal year20242025
Revenue93.01 bn KRW81.04 bn KRW
Gross profit46.46 bn KRW40.61 bn KRW
Operating income9.95 bn KRW7.46 bn KRW
EBIT7.58 bn KRW14.73 bn KRW
Net income5.08 bn KRW15.66 bn KRW
Diluted EPS – continuing operations95.47 KRW280.18 KRW

Full history since 2006, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About JW Shinyak Corporation

JW Shinyak Corporation, a pharmaceutical company, engages in the production and sale of medicines and medical supplies in South Korea. The company offers pharmaceutical products in the areas of dermatology, urology, pediatrics, otolaryngology, etc.; and cardiovascular, gastrointestinal, urinary, NSAIDs, antibiotics, anti-fungal, anti-viral, respiratory, antihistamines, steroid hormone, anti-obesity, and other products, as well as eye drops, and antitussives and expectorants. It also develops prostate cancer treatment, liver cancer treatment, rheumatoid arthritis treatment, etc. using immune cells. The company was founded in 1981 and is based in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.